Current Report Filing (8-k)
October 06 2016 - 5:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
September 30, 2016
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55016
|
|
26-0690857
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
IRS Employer
Identification No.)
|
655 Montgomery Street, Suite 900
San Francisco, CA
|
|
94111
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(408) 737-2734
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 1.02 Termination of a Material
Definitive Agreement
On September 30, 2016,
Lonza Walkersville, Inc. (“Lonza”) informed Amarantus Bioscience Holdings, Inc. (the “Company”) that the
Manufacturing Services Agreement dated as of July 14, 2015 between Lonza and the Company (the “MSA”) with respect to
the manufacture of the Company’s ESS product, had been terminated by Lonza pursuant to the terms of the MSA due to lack of
payment. The Company is seeking to work with Lonza to enter into a new MSA to provide for the initiation of its Phase 2 trial with
the US Army, subject to funding by the Company.
Item 8.01 Other Events
On August 26
th
,
2016, Lonza informed the Company that it had achieved current Good Manufacturing Practices (cGMP)-readiness for the Company’s
Engineered Skin Substitute Program.
In addition, the Company
extended the exclusivity period of its non-binding Letter of Intent (the "LOI”) with a commercial-stage wound-care
company to form a joint venture (the "JV") for the further development of the ESS program. The exclusivity period of
the LOI, has been extended for an additional 60 days to October 29, 2016.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
AMARANTUS BIOSCIENCE HOLDINGS, INC.
|
|
|
Date: October 6, 2016
|
By:
|
/s/
Gerald E. Commissiong
|
|
|
Name: Gerald E. Commissiong
Title: Chief Executive Officer
|
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024